SMARCB1 and lung cancer: Moreover, SMARCB1 downregulation seems to be an uncommon finding in primary lung cancer, as well as the immunophenotypic and morphological resemblance to SMARCB1-deficient carcinoma of the sinonasal tract, indicates that pulmonary SMARCB1-deficient carcinoma could be a distinct diagnostic entity.